drugset / Trial / NCT03689712

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

NCT03689712

Phase 3 Completed 455 enrolled Galera Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The purpose of the phase 3, clinical study is to determine if GC4419 (avasopasem manganese) administered prior to intensity-modulated radiation therapy (IMRT) reduces the severity of radiation induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.

Timeline

Start
2018-10-03
Primary completion
2021-08-13
Completion
2023-08-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Avasopasem manganese Other / unclassified 90 mg Intravenous

Indications